Company Overview - Suzhou Tianhua Super Clean Technology Co., Ltd. focuses on three main business areas: anti-static ultra-clean technology products, medical devices, and lithium battery materials [1] - In the first half of 2021, the company reported revenues of CNY 322 million from anti-static ultra-clean technology products, CNY 231 million from medical devices, and CNY 879 million from lithium battery materials [1] Lithium Battery Materials Development - Tianyi Lithium Industry plans to leverage the rapid growth of the new energy vehicle industry to expand its lithium battery materials business [2] - The first phase of the battery-grade lithium hydroxide project is set to complete 20,000 tons by August 2021, with a target of producing over 23,000 tons annually [2] - The second phase aims to achieve a production capacity of 25,000 tons of battery-grade lithium hydroxide by the end of 2021 [2] Resource Assurance and Supply Chain - Tianyi Lithium Industry has secured long-term supply agreements with suppliers, ensuring a supply of 145,000 to 175,000 tons of lithium concentrate in 2021 and 215,000 to 245,000 tons in 2022 [2] - The company has also established a strategy to expand upstream resources to meet future production capacity needs [2] Customer Structure and Market Strategy - Current customers include leading domestic cathode material manufacturers, with some products already exported [3] - The pricing model for transactions with customers is linked to publicly available prices for lithium carbonate and lithium hydroxide, with discounts based on order quantities [3] Future Strategic Planning - The company is committed to expanding its lithium concentrate supply both domestically and internationally, while also considering high-quality salt lake resources [3] - Tianyi Lithium Industry does not plan to invest in lithium mica resources due to long-term quality concerns [3]

Financial Performance - The company's revenue for Q3 2022 reached ¥4,797,665,466.11, representing a 438.66% increase year-over-year[3] - Net profit attributable to shareholders was ¥1,643,271,519.33, up 591.29% compared to the same period last year[3] - The basic earnings per share (EPS) for the quarter was ¥2.79, reflecting a 580.49% increase year-over-year[3] - The company's operating revenue for the third quarter reached ¥12,573,175,896.27, a significant increase of 441.47% compared to ¥2,322,054,165.19 in the same period last year[11] - The net profit for the period increased to ¥6,171,295,352.08, reflecting a growth of 371.89% from ¥1,307,773,624.35 in the previous year[11] - Net profit for Q3 2022 was ¥6,896,693,985.78, compared to ¥736,649,841.60 in Q3 2021, indicating a substantial increase of about 836.5%[22] - The total comprehensive income for Q3 2022 reached approximately CNY 6.99 billion, up from CNY 879 million in Q3 2021[23] Assets and Liabilities - Total assets at the end of the quarter amounted to ¥13,664,085,090.62, a 118.43% increase from the previous year[4] - Total assets as of Q3 2022 amounted to ¥13,664,085,090.62, up from ¥6,255,692,024.80 in the previous year, reflecting a growth of approximately 118.5%[21] - Total liabilities increased to ¥3,936,274,027.82 from ¥2,191,352,123.29, marking a rise of about 79.5%[21] - The company's equity attributable to shareholders increased to ¥7,552,546,432.78, up 132.86% from the end of the previous year[4] - The total equity attributable to shareholders of the parent company reached ¥7,552,546,432.78, compared to ¥3,243,441,652.18 in the previous year, reflecting an increase of about 132.2%[21] Cash Flow - Cash flow from operating activities for the year-to-date reached ¥6,460,585,921.09, a significant increase of 2,994.74%[3] - The net cash flow from operating activities was approximately CNY 6.46 billion, compared to a negative CNY 223 million in the same period last year[24] - Cash flow from operating activities for the current period was approximately CNY 12.83 billion, a substantial increase from CNY 1.68 billion in the previous year[24] - The company reported cash and cash equivalents at the end of the period amounting to approximately CNY 5.06 billion, up from CNY 602 million at the end of the previous year[25] Investments and Expenses - The company invested approximately CNY 1.14 billion in fixed assets and intangible assets during the period, compared to CNY 607 million in the same period last year[25] - Research and development expenses for Q3 2022 were ¥41,575,775.16, compared to ¥39,059,888.61 in Q3 2021, showing an increase of approximately 6.5%[22] - The sales expenses rose by 42.39% to ¥39,551,668.12, driven by increased personnel costs due to higher sales revenue[11] - Operating costs for Q3 2022 were ¥4,404,500,818.68, up from ¥1,502,219,759.84, which is an increase of approximately 194.5%[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 70,735, with the largest shareholder holding 25.75% of the shares[13] - The company distributed a cash dividend of 5 CNY per 10 shares, totaling 291,440,269 CNY based on a total share capital of 582,880,538 shares as of December 31, 2021[15] Strategic Plans - The company plans to continue expanding its market presence and investing in new technologies, particularly in the lithium industry[12] - The company plans to continue expanding its market presence through strategic stock issuance and acquisitions[15] Regulatory and Compliance - The company has received approval from the China Securities Regulatory Commission for its stock issuance to specific targets[17] - The company is in the process of resuming its stock issuance review after obtaining the necessary environmental impact assessment approval[17] - The company has faced interruptions in its stock issuance process due to regulatory inquiries and the investigation of its asset evaluation agency[17] Other Financial Metrics - Long-term borrowings surged by 706.77% to ¥450,000,000.00, primarily due to the acquisition of a 7% stake in subsidiary Tianyi Lithium Industry[11] - The company's deferred income increased by 254.54% to ¥17,840,215.88, attributed to government subsidies received by Tianyi Lithium Industry[11] - The company's goodwill increased to ¥245,205,327.09 from ¥231,782,121.70, representing a growth of about 5.9%[20] - The company's deferred income tax assets increased to ¥24,905,366.10 from ¥16,157,355.49, marking a growth of about 54.0%[20] - The company reported a financial expense of -¥4,879,982.50, a decrease of 119.78% compared to the previous year, mainly due to foreign exchange gains[11] - The company did not conduct an audit for the Q3 2022 report[26]

Financial Performance - The company reported a significant increase in revenue for the first half of 2022, achieving a total of 500 million yuan, representing a year-on-year growth of 25%[2]. - The company's operating revenue for the first half of 2022 reached ¥7,775,510,430.16, a significant increase of 443.22% compared to ¥1,431,383,298.20 in the same period last year[14]. - Net profit attributable to shareholders was ¥3,511,690,477.40, a significant increase of 1,023.42% from ¥312,588,747.38 in the previous year[14]. - The net profit after deducting non-recurring gains and losses was ¥3,501,258,372.76, up 1,229.76% from ¥263,299,277.83 year-on-year[14]. - The net cash flow from operating activities was ¥4,185,032,245.80, a remarkable turnaround from a negative cash flow of -¥72,783,590.70 in the same period last year, marking a 5,849.97% increase[14]. - Basic earnings per share increased to ¥6.00, up 971.43% from ¥0.56 in the previous year[14]. - The total profit for the same period was CNY 552,833.46 million, reflecting a year-on-year growth of 1,055.27%[20]. - The net profit for the first half of 2022 was CNY 592,542,538.90, a significant increase from CNY 154,643,447.73 in the same period of 2021, representing a growth of approximately 283%[115]. - Total comprehensive income for the first half of 2022 was CNY 1,362,498,037.00, with a net profit of CNY 592,542,538.90[126]. Market Expansion and Strategy - The company has provided a positive outlook for the second half of 2022, projecting a revenue growth of 20% to 30%[2]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[2]. - Strategic acquisitions are planned, with a focus on integrating complementary technologies to enhance product offerings[2]. - The company is actively expanding its market for anti-static ultra-clean technology products, enhancing customer relationships and service capabilities[22]. - The company has established a solid global marketing system and has built strong relationships with distributors and medical institutions, laying a foundation for sustainable development[37]. - The company has developed advanced production processes for lithium materials, improving product quality and stability through innovative technology[24]. Research and Development - The company has allocated 50 million yuan for research and development in new technologies for the upcoming fiscal year[2]. - The R&D center has been recognized as a key technology brand, contributing to multiple provincial innovation projects and fostering a culture of innovation[25]. - The company holds a total of 252 patents, including 35 invention patents, enhancing its competitive edge in the market[25]. - The company's R&D investment was ¥30,171,223.42, showing a slight increase of 0.48% compared to ¥30,026,902.15 in the previous year[39]. - The company’s research and development expenses were CNY 13,778,467.64 for the first half of 2022, slightly up from CNY 13,039,246.97 in the previous year, showing a growth of about 5.7%[115]. Financial Position and Assets - Total assets at the end of the reporting period were ¥11,276,232,518.57, an increase of 80.26% from ¥6,255,692,024.80 at the end of the previous year[14]. - Cash and cash equivalents increased by 753.19% to ¥2,851,018,034.45 from ¥334,160,943.60 in the previous year[39]. - The company's total liabilities were CNY 3.87 billion, compared to CNY 2.19 billion at the beginning of the year, marking an increase of about 77%[108]. - The total equity attributable to shareholders at the end of the previous year was CNY 4,064,339,990[121]. - The total equity at the end of the current period was CNY 5,881,056,658.00, indicating growth[122]. Risks and Challenges - The company has identified potential risks in supply chain disruptions and is implementing measures to mitigate these risks[2]. - The company faces macroeconomic risks due to its reliance on lithium materials, anti-static ultra-clean technology products, and medical devices, which are affected by economic cycles[58]. - Rising operational costs due to increasing raw material prices and employee compensation are a concern for the company[60]. - The company anticipates increased market competition as the industry matures and more players enter the market[59]. Corporate Governance and Compliance - The management team emphasized the importance of maintaining compliance with regulatory requirements in the medical device sector[2]. - The company has not reported any changes in its registered address or contact information during the reporting period[10]. - The company has not made any adjustments or restatements to previous years' accounting data[14]. - The company has maintained a stable cash dividend policy since its listing, ensuring clear profit distribution standards and procedures for shareholders[73]. Social Responsibility - The company actively engaged in social responsibility initiatives, including cash donations and material support during the pandemic[74]. - The company donated 2,000 protective suits, 65,000 FFP2 masks, and 100,000 surgical masks to various districts in Suzhou during the COVID-19 outbreak in February 2022[74].

Financial Performance - The company reported a revenue of 300 million RMB for the first half of 2021, representing a year-on-year increase of 15% compared to the same period in 2020[7]. - The net profit attributable to shareholders for the first half of 2021 was 50 million RMB, an increase of 20% year-on-year[7]. - The company achieved operating revenue of CNY 1,431,383,298.20, representing an increase of 87.86% compared to the same period last year[12]. - The net profit attributable to shareholders was CNY 312,588,747.38, reflecting a growth of 66.57% year-over-year[12]. - The company’s basic and diluted earnings per share were both CNY 0.56, an increase of 64.71% year-over-year[12]. - The company reported a total comprehensive income of ¥390,269,242.05 for the first half of 2021, compared to ¥193,605,726.13 in the first half of 2020, reflecting a growth of 102%[111]. - The total revenue from operating activities was CNY 1,038,281,011.01, up from CNY 923,622,917.72 in the first half of 2020, reflecting a growth of approximately 12.4%[116]. - The net profit for the first half of 2021 was CNY 154,643,447.73, an increase from CNY 104,767,870.16 in the same period of 2020, representing a growth of approximately 47.6%[113]. Market Expansion and Strategy - The company plans to expand its market presence in the lithium battery materials sector, targeting a growth rate of 30% in this segment over the next year[7]. - The company is exploring potential mergers and acquisitions to enhance its technological capabilities and market reach[7]. - Future guidance suggests a projected revenue growth of 20% for the second half of 2021, driven by increased demand in the clean technology sector[7]. - The company plans to enhance market expansion efforts in the lithium battery materials, medical devices, and electronic information sectors, leveraging production and supply advantages[26]. - The company is actively expanding its market for anti-static ultra-clean technology products and enhancing its R&D capabilities[18]. - The company is focused on enhancing shareholder rights and has established a robust corporate governance structure to protect the interests of minority shareholders[70]. Research and Development - Research and development expenses accounted for 10% of total revenue, reflecting the company's commitment to innovation and new product development[7]. - The company emphasizes continuous investment in R&D to meet and guide customer demands, reinforcing its competitive edge in the market[22]. - Research and development expenses for the first half of 2021 amounted to ¥30,026,902.15, slightly up from ¥29,609,271.49 in the same period of 2020[109]. Financial Position and Assets - The company reported a total asset value of CNY 4,213,187,762.58, up 69.15% from the end of the previous year[12]. - The net assets attributable to shareholders reached CNY 2,221,532,304.19, marking an 83.13% increase compared to the previous year[12]. - The company’s cash flow from operating activities was negative at CNY -72,783,590.70, a decline of 122.52% from the previous year[12]. - The company reported cash and cash equivalents of ¥584,422,377.21 as of June 30, 2021, compared to ¥231,325,022.01 at the end of 2020, representing a 153.1% increase[102]. - The company’s accounts receivable increased to ¥377,490,058.52 from ¥161,717,754.65, a growth of 133.3%[102]. - The company’s total liabilities reached CNY 1,594,936,296.27, up from CNY 1,004,109,162.08, reflecting a growth of approximately 58.9%[104]. Risks and Challenges - The company faces risks related to supply chain disruptions and is implementing measures to mitigate these risks[2]. - The company faces market competition risks due to an expanding market and increasing competition, which may affect product pricing and market share[56]. - The company is addressing rising cost risks by optimizing internal organization and enhancing personnel efficiency to maintain profitability[57]. - The company is exposed to foreign exchange risks due to its export business primarily settled in USD, and it plans to use hedging tools to mitigate these risks[59]. Corporate Governance and Social Responsibility - The company actively participates in social responsibility initiatives, donating medical supplies during the COVID-19 pandemic and supporting impoverished students[70]. - The company held an annual general meeting with a participation rate of 39.65% on May 12, 2021[65]. - The company has no plans to distribute cash dividends or issue bonus shares for the current fiscal year[2]. Share Issuance and Capital Management - The company raised RMB 765.05 million through a private placement of 31,604,538 shares at RMB 24.68 per share, primarily to invest in the second phase of the lithium hydroxide project[21]. - The total number of shares increased from 551,276,000 to 582,880,538 after the issuance of 31,604,538 new shares[86]. - The company completed the issuance of 31,604,538 shares to specific investors, which was approved by the China Securities Regulatory Commission on March 10, 2021[83]. - The company has no plans for share repurchase during the reporting period[87]. Inventory and Supply Chain Management - The company employs a centralized procurement model for raw materials, ensuring stable supply and cost management[25]. - The company conducts monthly inventory counts to ensure accuracy and reflects any discrepancies in the current year's profit or loss[175]. - Inventory is classified into raw materials, work in progress, and finished goods, with a perpetual inventory system in place[176]. Accounting and Financial Reporting - The financial statements are prepared based on the enterprise accounting standards, reflecting the company's financial position and operating results accurately[137]. - The company recognizes deferred tax assets or liabilities in the consolidated balance sheet due to temporary differences arising from unrealized internal sales profits[144]. - The company’s consolidated financial statements include all subsidiaries under its control, ensuring a comprehensive view of its financial health[142].